Transactivation of ErbB receptors by leptin in the cardiovascular system: Mechanisms, consequences and target for therapy

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 616-624

  Bełtowski, Jerzy ^a   Jazmroz Wiśniewska, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Atherosclerosis; Epidermal growth factor receptor; ErbB receptors; Leptin; Metabolic syndrome; Obesity; Phosphoinositide 3 kinase; Restenosis; Smooth muscle cells

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; NORADRENALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRORENIN; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; THROMBIN;

ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CALCIUM CELL LEVEL; CARDIOVASCULAR SYSTEM; DIMERIZATION; ENDOCYTOSIS; ENZYME INHIBITION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; IN VIVO STUDY; KIDNEY; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RESTENOSIS; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; LEPTIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84894095588     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282004140213155050     Document Type: Article

References (133)

1. Wadugu B, Kühn B. he role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol 2012; 302: H2139-47.
2. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55: 685-96.
3. Yan X, Morgan JP. Neuregulin1 as novel therapy for heart failure. Curr Pharm Des 2011; 17: 1808-17.
4. Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol 2008; 44: 831-54.
5. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011; 121: 3797-803.
6. Batchu SN, Korshunov VA. Novel tyrosine kinase signaling pathways: implications in vascular remodeling. Curr Opin Nephrol Hypertens 2012; 21: 122-7.
7. Krug AW, Pojoga LH, Williams GH, Adler GK. Cell membraneassociated mineralocorticoid receptors? New evidence. Hypertension. 2011; 57: 1019-25.
8. Yogi A, O'Connor SE, Callera GE, Tostes RC, Touyz RM. Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension. Curr Opin Nephrol Hypertens 2010; 19: 169-76.
9. Bełtowski J, Łowicka E. EGF receptor as a drug target in arterial hypertension. Mini Rev Med Chem. 2009; 9: 526-38.
10. Melenhorst WB, Mulder GM, Xi Q, et al. Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension 2008; 52: 987-93.
11. Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol 2012; 32: 1766-70.
12. Basu S, Nachat-Kappes R, Caldefie-Chézet F, Vasson MP. Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations. Antioxid Redox Signal 2013; 18: 323-60.
13. Grossmann ME, Cleary MP. The balance between leptin and adiponectin in the control of carcinogenesis-focus on mammary tumorigenesis. Biochimie 2012; 94: 2164-71.
14. Bełtowski J, Jamroz-Wiśniewska A. Role of epidermal growth factor receptor (EGFR) in the pathogenesis and treatment of arterial hypertension. Biomed Rev 2007; 18: 1-26.
15. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31-53.
16. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 2010; 90: 1507-46.
17. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012; 92: 689-737.
18. Wymann MP, Schultz C. The chemical biology of phosphoinositide 3-kinases. Chembiochem 2012; 13: 2022-35.
19. Falasca M, Maffucci T. Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem J 2012; 443: 587-601.
20. Ghigo A, Morello F. Phosphoinositide 3-Kinases in health and disease Subcell Biochem 2012; 58: 183-213.
21. Wilson KJ, Mill C, Lambert S, et al. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 2012; 30: 107-16.
22. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379: 557-60.
23. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-8.
24. Grossmann C, Gekle M. Interaction between mineralocorticoid receptor and epidermal growth factor receptor signaling. Mol Cell Endocrinol 2012; 350: 235-41.
25. Almendro V, García-Recio S, Gascón P. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets 2010; 11: 1169-80.
26. Iebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol 2011; 331: 222-31.
27. Seta K, Sadoshima J. Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced transactivation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 9019-26.
28. Zhai P, Galeotti J, Liu J, et al. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res 2006; 99: 528-36.
29. Tilley DG, Kim IM, Patel PA, Violin JD, Rockman HA. β-Arrestin Mediates β1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem 2009; 284: 20375-86.
30. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res 2004; 94: 68-76.
31. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 2004; 95: 989-97.
32. Schreier B, Döhler M, Rabe S, et al. Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1. Arterioscler Thromb Vasc Biol 2011; 31: 1643-52.
33. Yogi A, Callera GE, Aranha AB, et al. Sphingosine-1-phosphateinduced inflammation involves receptor tyrosine kinase transactivation in vascular cells: upregulation in hypertension. Hypertension 2011; 57: 809-18.
34. Jagadeesha DK, Takapoo M, Banfi B, Bhalla RC, Miller FJ. Nox1 transactivation of epidermal growth factor receptor promotes Ncadherin shedding and smooth muscle cell migration. Cardiovasc Res 2012; 93: 406-13.
35. Abdallah RT, Keum JS, El-Shewy HM, et al. Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem 2010; 285: 35206-15.
36. Burch ML, Ballinger ML, Yang SN, et al. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor. J Biol Chem 2010; 285: 26798-805.
37. Hsieh HL, Tung WH, Wu CY, et al. Thrombin induces EGF receptor expression and cell proliferation via a PKCδ/c-Src-dependent pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2009; 29: 1594-601.
38. Singh NK, Wang D, Kundumani-Sridharan V, Van Quyen D, Niu J, Rao GN. 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling. J Biol Chem 2011; 286: 22478-88.
39. Nguyen AN, Jansson K, Sánchez G, et al. Ouabain activates the Na-K-ATPase signalosome to induce autosomal dominant polycystic kidney disease cell proliferation. Am J Physiol Renal Physiol 2011; 301: F897-906.
40. Liu L, Zhao X, Pierre SV, Askari A. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes. Am J Physiol Cell Physiol 2007; 293: C1489-97.
41. Shibasaki Y, Matsubara H, Nozawa Y, et al. Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of SHP-1 tyrosine phosphatase. Hypertension 2001; 38: 367-72.
42. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol 2012; 165: 1390-400.
43. Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab 2004; 15: 241-3.
44. Eguchi S, Frank GD, Mifune M, Inagami T. Metalloproteasedependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem Soc Trans 2003; 31):1198-202.
45. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 2006; 186: 38-53.
46. 2+ influx in afferent arterioles. Hypertension 2002; 40: 700-6.
47. Hao L, Nishimura T, Wo H, Fernandez-Patron C. Vascular responses to α1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler Thromb Vasc Biol 2006; 26: 819-25.
48. Nagareddy PR, MacLeod KM, McNeill JH. GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats. Cardiovasc Res 2010; 87: 177-86.
49. Lucchesi PA, Sabri A, Belmadani S, Matrougui K. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation 2004; 110: 3587-93.
50. Chansel D, Ciroldi M, Vandermeersch S, et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J 2006; 20: 1936-8.
51. Flamant M, Tharaux PL, Placier S, et al. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 2003; 17: 327-9.
52. Schreier B, Rabe S, Schneider B, et al. Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes Arterial Hypotension and Cardiac Hypertrophy. Hypertension (in press).
53. Touyz RM, Wu XH, He G, Salomon S, Schiffrin EL. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 2002; 39: 479-85.
54. Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 2000; 20: 2539-45.
55. Li Y, Lévesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 2010; 299: H1959-67.
56. Sandoval YH, Li Y, Anand-Srivastava MB. Transactivation of epidermal growth factor receptor by enhanced levels of endogenous angiotensin II contributes to the overexpression of Giα proteins in vascular smooth muscle cells from SHR. Cell Signal 2011; 23: 1716-26.
57. Florian JA, Watts SW. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol 1999; 276: H976-83.
58. Florian JA, Dorrance A, Webb RC, Watts SW. Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am. J. Physiol. Regul. Integr. Comp Physiol 2001; 281: R878-86.
59. Northcott C, Florian JA, Dorrance A, Watts SW. Arterial epidermal growth factor receptor expression in deoxycorticosterone acetatesalt hypertension. Hypertension 2001; 38: 1337-41.
60. Kim J, Lee CK, Park HJ, et al. Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinasemediated mitogen-activated protein kinase pathway in hypertensive rats. J Pharmacol Sci 2006; 101: 135-43.
61. Benter IF, Canatan H, Benboubetra M, Yousif MH, Akhtar S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascul Pharmacol 2009; 51: 101-9.
62. Swaminathan N, Sambhi MP. Induction of high affinity epidermal growth factor binding in the aorta of Dahl hypertensive rats fed with high salt diet. Hypertens Res 1996; 19: 65-8.
63. Ying WZ, Sanders PW. Enhanced expression of EGF receptor in a model of salt-sensitive hypertension. Am J Physiol Renal Physiol 2005; 289: F314-21.
64. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002; 106: 909-12.
65. Kagiyama S, Qian K, Kagiyama T, Phillips MI. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 2003; 41: 824-9.
66. Lautrette A, Li S, Alili R, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med 2005; 11: 867-74.
67. François H, Placier S, Flamant M, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 2004; 18: 926-8.
68. Helle F, Jouzel C, Chadjichristos C, et al. Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. Am J Physiol Renal Physiol 2009; 297: F191-9.
69. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011; 57: 238-44.
70. Dahal BK, Cornitescu T, Tretyn A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 158-67.
71. Toby IT, Chicoine LG, Cui H, Chen B, Nelin LD. Hypoxiainduced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activation. Am J Physiol Lung Cell Mol Physiol 2010; 298: L600-6.
72. Overbeek MJ, Boonstra A, Voskuyl AE, et al. Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study. Arthritis Res Ther 2011; 13: R61.
73. Norton CE, Broughton BR, Jernigan NL, Walker BR, Resta TC. Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H Oxidase 2. Antioxid Redox Signal (in press).
74. Zheleznova NN, Wilson PD, Staruschenko A. Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta 2011; 1812): 1301-13.
75. Melenhorst WB, Mulder GM, Xi Q, et al. Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension 2008; 52: 987-93.
76. Zeng F, Singh AB, Harris RC. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res 2009; 315: 602-10.
77. Cui XL, Ding Y, Alexander LD, et al. Oxidative signaling in renal epithelium: Critical role of cytosolic phospholipase A2 and p38(SAPK). Free Radic Biol Med 2006; 41: 213-21.
78. Chen J, Chen JK, Neilson EG, Harris RC. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol 2006; 17: 1615-23.
79. Alexander LD, Ding Y, Alagarsamy S, Cui XL, Douglas JG. Arachidonic acid induces ERK activation via Src SH2 domain association with the epidermal growth factor receptor. Kidney Int 2006; 69: 1823-32.
80. Lee JS, Kim SY, Kwon CH, Kim YK. EGFR-dependent ERK activation triggers hydrogen peroxide-induced apoptosis in OK renal epithelial cells. Arch. Toxicol 2006; 80: 337-46.
81. Dong J, Ramachandiran S, Tikoo K, Jia Z, Lau SS, Monks TJ. EGFR-independent activation of p38 MAPK and EGFR-dependent activation of ERK1/2 are required for ROS-induced renal cell death. Am J Physiol Renal Physiol 2004; 287: F1049-58.
82. 2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells. Am J Physiol Renal Physiol 2004; 286: F858-65.
83. Zhuang S, Yan Y, Han J, Schnellmann RG. p38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation of renal epithelial cells after oxidant injury. J Biol Chem 2005; 280: 21036-42.
84. Gow CB, Phillips PA, Chandler KD, Moore GP. Hormonal, fluid, and electrolyte responses of sheep during chronic intravenous infusion of epidermal growth factor. Am J Physiol 1993; 265: R203-10.
85. Bens M, Chassin C, Vandewalle A. Regulation of NaCl transport in the renal collecting duct: lessons from cultured cells. Pflugers Arch 2006; 453: 133-46.
86. Harris RC, Hoover RL, Jacobson HR, Badr KF. Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest 1988; 82: 1028-39.
87. Gekle M, Freudinger R, Mildenberger S, Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids 2002; 67: 499-504.
88. Endo Y, Suzuki M, Yamada H, et al. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling. Cell Metab 2011; 13: 550-61.
89. Taruno A, Niisato N, Marunaka Y. Hypotonicity stimulates renal epithelial sodium transport by activating JNK via receptor tyrosine kinases. Am J Physiol Renal Physiol 2007; 293: F128-38.
90. Liu L, Duke BJ, Malik B, Yue Q, Eaton DC. Biphasic regulation of ENaC by TGF-α} and EGF in renal epithelial cells. Am J Physiol Renal Physiol 2009; 296: F1417-27.
91. +-ATPase activity by a tyrosine phosphorylation process in rat proximal convoluted tubule. J Physiol 1997; 498: 99-108.
92. +-ATPase. Peptides 2006; 27: 3234-44.
93. +-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 2006; 290: R529-35.
94. Markadieu N, Crutzen R, Blero D, Erneux C, Beauwens R. Hydrogen peroxide and epidermal growth factor activate phosphatidylinositol 3-kinase and increase sodium transport in A6 cell monolayers. Am J Physiol Renal Physiol 2005; 288: F1201-12.
95. Jamroz-Wiśniewska A, Wójcicka G, Łowicka E, Ksia{ogonek}ek M, Betowski J. Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: role in leptin-induced hypertension. Biochem Pharmacol 2008; 75: 1623-38.
96. Azar ZM, Mehdi MZ, Srivastava AK. Insulin-like growth factor type-1 receptor transactivation in vasoactive peptide and oxidantinduced signaling pathways in vascular smooth muscle cells. Can J Physiol Pharmacol 2007; 85: 105-11.
97. Bach LA. The insulin-like growth factor system in kidney disease and hypertension. Curr Opin Nephrol Hypertens 2012; 21: 86-91.
98. Shida D, Kitayama J, Mori K, Watanabe T, Nagawa H. Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Re. 2005; 65: 9159-63.
99. 2-terminal kinase activation. Endocrinology 2006; 147: 4505-16.
100. Beales IL, Ogunwobi OO. Leptin synergistically enhances the antiapoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 2007; 274: 60-8.
101. Ogunwobi OO, Beales IL. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and TGFα mediated transactivation of the epidermal growth factor receptor. Br J Biomed Sci 2008; 65: 121-7.
102. Saxena NK, Taliaferro-Smith L, Knight BB, et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008; 68: 9712-22.
103. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, Sharma D. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer 2011; 18: 413-28.
104. Konturek PC, Brzozowski T, Sulekova Z, et al. Role of leptin in ulcer healing. Eur J Pharmacol 2001; 414: 87-97.
105. Chao HH, Hong HJ, Liu JC, et al. Leptin stimulates endothelin-1 expression via extracellular signal-regulated kinase by epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Eur J Pharmacol 2007; 573: 49-54.
106. 2 activation in gastric mucosal protection against ethanol cytotoxicity involves epidermal growth factor receptor transactivation. Inflammopharmacology 2009; 17: 6-14.
107. 2 in leptin protection of salivary gland acinar cells against ethanol cytotoxicity. J Physiol Pharmacol 2009; 60: 49-55.
108. Yousif MH, Benter IF, Akhtar S. The role of tyrosine kinasemediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 2005; 25: 69-78.
109. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S. Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol 2005; 145: 829-36.
110. Benter IF, Yousif MH, Hollins AJ, Griffiths SM, Akhtar S. Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 2005; 42: 284-91.
111. Benter IF, Benboubetra M, Hollins AJ, Yousif MH, Canatan H, Akhtar S. Early inhibition of EGFR signaling prevents diabetesinduced up-regulation of multiple gene pathways in the mesenteric vasculature. Vascul Pharmacol 2009; 51: 236-45.
112. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008; 57: 1629-37.
113. Palen DI, Matrougui K. Role of elevated EGFR phosphorylation in the induction of structural remodelling and altered mechanical properties of resistance artery from type 2 diabetic mice. Diabetes Metab Res Rev 2008; 24: 651-6.
114. Choi SK, Galán M, Partyka M, Trebak M, Belmadani S, Matrougui K. Chronic inhibition of epidermal growth factor receptor tyrosine kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2) augments vascular response to limb ischemia in type 2 diabetic mice. Am J Pathol 2012; 180: 410-8.
115. Nagareddy PR, MacLeod KM, McNeill JH. GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats. Cardiovasc Res 2010; 87: 177-86.
116. Prada PO, Ropelle ER, Mourão RH, et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes 2009; 58: 2910-9.
117. Li Q, Hosaka T, Shikama Y, et al. Heparin-binding EGF-like growth factor (HB-EGF) mediates 5-HT-induced insulin resistance through activation of EGF receptor-ERK1/2-mTOR pathway. Endocrinology 2012; 153: 56-68.
118. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004; 37: 449-71.
119. Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 2009; 82: 261-71.
120. Carnevale D, Vecchione C, Mascio G, et al. PI3Kγ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. Cardiovasc Res 2012; 93: 200-9.
121. Guo D, Kassiri Z, Basu R, et al. Loss of PI3Kγ enhances cAMPdependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res 2010; 107: 1275-89.
122. Perino A, Ghigo A, Ferrero E, et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol Cell 2011; 42: 84-95.
123. Ghigo A, Perino A, Mehel H, et al. Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 2012; 126: 2073-83.
124. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006; 393: 7-20.
125. Beltowski J, Wójcicka G, Wojtak A. Effect of experimental hyperhomocysteinemia on plasma lipid profile, insulin sensitivity and paraoxonase 1 in the rat. Adipobiology 2012; 4: 77-84.
126. Bełtowski J, Jamroz-Wiśniewska A. Role of epidermal growth factor receptor (EGFR) in the pathogenesis and treatment of arterial hypertension. Biomed Reviews 2007; 18: 1-26.
127. Bełtowski J, Łowicja E. EGF Receptor as a drug target in arterial hypertension. Mini Rev Medic Chem 2009; 9: 526-38.
128. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284: 54-65.
129. Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 2008; 149: 9-14.
130. Eisenberg A, Biener E, Charlier M, et al. Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett 2004; 565: 139-42.
131. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008; 105: 956-64.
132. Mifune M, Ohtsu H, Suzuki H, et al. Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. Am J Physiol Cell Physiol 2004; 287: C807-13.
133. Shan J, Nguyen TB, Totary-Jain H, Dansky H, Marx SO, Marks AR. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci USA 2008; 105: 19006-11.